reports
STERIS Announces Dividend of $0.52 per share
STERIS Announces Dividend of $0.52 per share DUBLIN, IRELAND, May 01, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on June 26, 2024, to shareholders of record at the close of business on June 12, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at . STERIS is a leading global provider of products and services that support patient care with an emphasis on infection preve...
STERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Fu...
STERIS to Host a Conference Call for Fiscal 2024 Fourth Quarter and Full Year Financial Results on May 9, 2024 DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m. ET on May 9, 2024. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing ...
STERIS to Sell Dental Segment to an affiliate of Peak Rock Capital
STERIS to Sell Dental Segment to an affiliate of Peak Rock Capital Transaction expected to close in STERIS’s first quarter of fiscal 2025Divestiture allows STERIS to focus on Customers within core marketsProceeds primarily to be used to repay debt DUBLIN, IRELAND, April 11, 2024 (GLOBE NEWSWIRE) -- ) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has entered into a definitive agreement to divest its Dental segment to Peak Rock Capital, a leading middle-market private investment firm, for $787.5 million (the “Transaction”). The Transaction is structu...
STERIS Announces Financial Results for Fiscal 2024 Third Quarter
STERIS Announces Financial Results for Fiscal 2024 Third Quarter Third quarter revenue increases 15% as reported; 10% constant currency organicAs reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22Fiscal 2024 outlook updated DUBLIN, IRELAND, Feb. 07, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 third quarter ended December 31, 2023. Revenue as reported for the quarter increased 15% to $1.40 billion compared with $1.22 billion in the third quarter of fisc...
STERIS Announces Dividend of $0.52 per share
STERIS Announces Dividend of $0.52 per share DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on March 22, 2024, to shareholders of record at the close of business on February 23, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at . STERIS is a leading global provider of products and services that support patient care with an emphasis on infection...
STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financ...
STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024 DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m. ET on February 8, 2024. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results wil...
STERIS Announces Financial Results for Fiscal 2024 Second Quarter
STERIS Announces Financial Results for Fiscal 2024 Second Quarter Second quarter revenue growth of 12% as reported and 8% constant currency organicAs reported diluted earnings per share increased to $1.16; adjusted earnings increased to $2.03Fiscal 2024 outlook maintained DUBLIN, IRELAND, Nov. 07, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 second quarter ended September 30, 2023. Revenue as reported for the quarter increased 12% to $1.34 billion compared with $1.20 billion in the second quarter of...
STERIS Announces Dividend of $0.52 per share
STERIS Announces Dividend of $0.52 per share DUBLIN, IRELAND, Oct. 31, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on December 21, 2023, to shareholders of record at the close of business on November 21, 2023. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life ...
STERIS to Host a Conference Call for Fiscal 2024 Second Quarter Financ...
STERIS to Host a Conference Call for Fiscal 2024 Second Quarter Financial Results on November 8, 2023 DUBLIN, IRELAND, Oct. 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 second quarter financial results at 9:00 a.m. ET on November 8, 2023. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results w...
STERIS to Present at the Morgan Stanley Healthcare Conference
STERIS to Present at the Morgan Stanley Healthcare Conference DUBLIN, IRELAND , Aug. 30, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 13, 2023. Dan Carestio, President and CEO of STERIS will present at 8:10 a.m. Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on STERIS’s investor relations website at About STERIS STERIS is a leading global provider of products and services that suppo...
STERIS Completes the Acquisition of Surgical Instrumentation Assets fr...
STERIS Completes the Acquisition of Surgical Instrumentation Assets from BD DUBLIN, IRELAND, Aug. 02, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it has completed the previously announced acquisition of the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from BD (Becton, Dickinson and Company) (NYSE:BDX). “We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS’s product offerings within our Healthcare segment,” said...
STERIS Announces Financial Results for Fiscal 2024 First Quarter
STERIS Announces Financial Results for Fiscal 2024 First Quarter First quarter revenue growth of 11% as reported and constant currency organicAs reported diluted earnings per share increased to $1.25; adjusted earnings increased to $2.00Fiscal 2024 outlook updated to reflect acquisition of BD surgical instrumentation assets DUBLIN, IRELAND, Aug. 01, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 first quarter ended June 30, 2023. Revenue as reported for the quarter increased 11% to $1.28 billion compar...
STERIS to Host a Conference Call for Fiscal 2024 First Quarter Financi...
STERIS to Host a Conference Call for Fiscal 2024 First Quarter Financial Results on August 2, 2023 DUBLIN, IRELAND, July 19, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 first quarter financial results at 9:00 a.m. ET on August 2, 2023. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be...
STERIS Expands Healthcare Products Offering with Acquisition of Surgic...
STERIS Expands Healthcare Products Offering with Acquisition of Surgical Instrumentation Assets from Becton, Dickinson and Company for $540 million A natural extension for STERIS in the operating room and sterile processing departmentA primarily consumables product portfolioTransaction expected to close by September 30, 2023 DUBLIN, IRELAND , June 20, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has signed a definitive agreement to purchase the surgical instrumentation, laparoscopic instrumentation and sterilization contain...
STERIS Announces Financial Results for Fiscal 2023 Fourth Quarter and ...
STERIS Announces Financial Results for Fiscal 2023 Fourth Quarter and Full Year Fourth quarter as reported revenue increased 14%; 16% constant currency organic revenue growthFourth quarter as reported earnings per share of $1.88; adjusted EPS of $2.30Fiscal 2024 Outlook Provided DUBLIN, IRELAND , May 10, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 fourth quarter and full year ended March 31, 2023. Revenue as reported for the quarter increased 14% to $1.38 billion compared with $1.21 billion in the four...
STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors
STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. “We are pleased to welcome Dr. Alegria to our Board,” said Mohsen Sohi, Chairman of STERIS. “She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition.” Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team foc...
STERIS Announces $500 million Share Repurchase Authorization and Decla...
STERIS Announces $500 million Share Repurchase Authorization and Declares $0.47 per share Dividend DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that STERIS's Board of Directors has authorized a new share buyback program for the purchase of up to $500 million of the Company's ordinary shares. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at any time. In addition, the Company will distribute a quarterly in...
STERIS to Host a Conference Call for Fiscal 2023 Fourth Quarter and Fu...
STERIS to Host a Conference Call for Fiscal 2023 Fourth Quarter and Full Year Financial Results on May 11, 2023 DUBLIN, IRELAND, April 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 fourth quarter and full year financial results at 9:00 a.m. ET on May 11, 2023. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailin...
STERIS Announces Financial Results for Fiscal 2023 Third Quarter
STERIS Announces Financial Results for Fiscal 2023 Third Quarter As reported revenue increased 1%; 7% constant currency organic revenue growthAs reported earnings per share of $1.24; adjusted EPS of $2.02Updated outlook provided DUBLIN, IRELAND, Feb. 08, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 third quarter ended December 31, 2022. Revenue as reported for the quarter increased 1% to $1.22 billion compared with $1.21 billion in the third quarter of fiscal 2022. Constant currency organic revenue (see...
STERIS Declares $0.47 per share Dividend
STERIS Declares $0.47 per share Dividend DUBLIN, IRELAND, Feb. 01, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.47 per share. The dividend is payable March 23, 2023 to shareholders of record at the close of business on February 24, 2023. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.